PAD Profile : Betamethasone - Mucositis - chemotherapy / radiotherapy induced

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Betamethasone - Mucositis - chemotherapy / radiotherapy induced

Keywords :

Oropharyngeal lesions, oral ulceration, oral inflammation

Traffic Light Status

Status :

Red

Important

Formulations :

Important Information :

Patients on everolimus treatment. Used as a mouthwash, in line with St Luke's SACT protocols

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

Comments :

No comments returned.

Documents :

No guidelines returned.

No additional documents returned.

Date

Committee Name

Narrative

05 February 2025

Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.

12. Ear, Nose and Oropharynx

12.03.01. Drugs for oral ulceration and inflammation